December 2023

New targeted therapies offer certain patients with non–small cell lung cancer more second-line treatment options.

Delivering hazardous drugs safely is complex but essential for the welfare of our health care workers and our patients.

The introduction of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma is considered one of the most significant advancements in the past decade.

"Differential diagnoses in patients with bicytopenia—particularly those with preserved platelets—are broad and require careful physical examination."

Diversity, equity, and inclusion must be a centerpiece of nursing recruitment and retention.

For patients with gynecologic cancer for whom platinum-based chemotherapy is no longer effective, antibody-drug conjugates are an exciting second-line option.